Q1 FY27 Results: Revenue up 26% YoY, PAT up 31% YoY

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

CONCORDBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹1418.50

prior close

₹1444.40

announcement price

After-mkt

timing

Nifty Smallcap 250market+1.4%-2.0% vs market

Pharmaceuticals peers, median of 163sector+1.0%-1.6% vs sector

On the reaction day the stock moved 2.0 pts less than Nifty Smallcap 250 and 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.6

10m

-2.8

15m

-3.3

30m

-1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6+1.4-2.0+1.0-1.6

Next day

-0.1+1.5-1.7+0.8-1.0

-2.4+2.2-4.6+0.3-2.7

-3.1+2.4-5.5+0.7-3.8

-3.8+2.4-6.2+1.5-5.2

+0.5+2.4-1.8+1.3-0.8

+2.0+2.3-0.3+1.5+0.5

15d

+8.7+2.5+6.2+0.8+7.9

+2.2+2.9-0.8+1.6+0.6

-4.6-1.5-3.2+1.9-6.5

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 163Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Concord Biotech posted strong Q1 FY27 (June 30, 2026) consolidated results. Revenue from operations rose 26% YoY to Rs 25,749 lakhs (from Rs 20,399 lakhs). Profit after tax grew 31% YoY to Rs 5,770 lakhs (from Rs 4,406 lakhs). Total comprehensive income stood at Rs 7,476 lakhs. EPS was Rs 5.52 versus Rs 4.21. Standalone revenue grew 28% to Rs 26,052 lakhs and PAT grew 44% to Rs 6,119 lakhs. Auditors BSR & Co issued an unmodified limited review. No defaults, related party transactions or audit qualifications reported. Cellimmune Biotech became a wholly owned subsidiary in April 2026.

Likely market impact

Strong quarter with double-digit revenue and profit growth signals healthy demand and margin expansion for shareholders.